Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UB VV111

Next Previous
X
Search
Drug Profile

UB VV111

Alternative Names: UB VV111 with RACR-CD19 CAR T cells; UB-VV111

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Umoja Biopharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Haematological malignancies

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 31 Jul 2024 Umoja Biopharma plans a phase I trial for B-cell lymphoma and Chronic lymphocytic leukemia (Second line therapy or greater, Combination therapy) in November 2024 (NCT06528301)
  • 04 Jan 2024 AbbVie collaborates with Umoja Biopharma for UB-VV111.
  • 11 Dec 2023 pharmacodynamics and adverse events data from a preclinical trial in Hematological malignancies released by Umoja Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top